← Back to Search

Medication Adherence Intervention for Myocardial Ischemia and Rheumatic Diseases (SEPPRMACI-ARM Trial)

N/A

Waitlist Available

Led By Liron Caplan, MD PhD

Research Sponsored by VA Office of Research and Development

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 year

Awards & highlights

SEPPRMACI-ARM Trial Summary

This trial will test a medication adherence intervention for Veterans with ischemic heart disease and rheumatic disease. The intervention will use personalized text messages and telephone calls to remind patients to refill their medications.

Who is the study for?

This trial is for Veterans with ischemic heart disease who've had a PCI or are starting anti-rheumatic medication. They must be taking specific meds, get care from the VA, and have a VA-assigned primary care provider. It's not for those only diagnosed via catheterization, prisoners, pregnant women, terminally ill patients, those using non-VA medicine sources or in nursing facilities, or individuals with impaired decision-making.Check my eligibility

What is being tested?

The study tests an adherence intervention called VA SEPPRMACI-ARM to improve how well Veterans with IHD follow their medication plans after PCI or when starting anti-rheumatic drugs. It uses personalized texts and calls to remind patients about refills and escalates to personal contact if they miss doses.See study design

What are the potential side effects?

Since this trial focuses on improving medication adherence rather than testing new medications themselves, side effects would relate primarily to the underlying treatments for IHD or rheumatic diseases rather than the intervention being tested.

SEPPRMACI-ARM Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Proportion of Days Covered (PDC)

Secondary outcome measures

Cardiovascular Events (CVE)

Incremental Cost Effectiveness (ICE)

SEPPRMACI-ARM Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Experimental GroupExperimental Treatment1 Intervention

This group will undergo the intervention as described in the protocol

Group II: Control GroupActive Control1 Intervention

This group will not receive the intervention, they will receive usual care

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

VA Office of Research and DevelopmentLead Sponsor

1,611 Previous Clinical Trials

3,300,015 Total Patients Enrolled

1 Trials studying Rheumatic Diseases

12 Patients Enrolled for Rheumatic Diseases

Liron Caplan, MD PhDPrincipal InvestigatorRocky Mountain Regional VA Medical Center, Aurora, CO

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Could you apprise me of the current number of healthcare facilities involved in this experiment?

"The research team is currently recruiting patients from 4 different sites, including Baltimore, San Francisco and Aurora. To minimize the hassle of travel if you decide to join this clinical trial, it would be beneficial to select a nearby location."

Answered by AI

Does the research include elderly individuals aged 70 and over?

"According to the established criteria, those wishing to participate need to be between 18 and 95 years old. This trial is one of 48 specifically intended for minors while there are 662 research studies catered towards seniors."

Answered by AI

Would I be qualified to join this research experiment?

"For this clinical trial, 5269 individuals aged 18-95 who have been diagnosed with myocardial ischemia can be enrolled. Candidates must meet additional criteria such as undergoing PCI or taking DMARDs like statins, beta blockers and thienopyridines (dual platelet inhibitors) for the IHD intervention and oral methotrexate, sulfasalazine, azathioprine or leflunomide for the DMARD intervention."

Answered by AI

Are there currently vacancies for participation in this experiment?

"The details of this clinical trial, first published on October 1st 2016 and last updated in March 15th 2022, signify that it is not presently enrolling participants. However, there are 703 other medical studies searching for volunteers."

Answered by AI

Recent research and studies

JCR: Journal of Clinical RheumatologyJournal

Initiation of Disease-modifying Therapies in Rheumatoid Arthritis Is Associated with Changes in Blood Pressure

Baker, Joshua F., Brian Sauer, Chia-Chen Teng, Michael George, Grant W. Cannon, Said Ibrahim, Amy Cannella, et al.. 2018. “Initiation of Disease-modifying Therapies in Rheumatoid Arthritis Is Associated with Changes in Blood Pressure”. JCR: Journal of Clinical Rheumatology. Ovid Technologies (Wolters Kluwer Health). doi:10.1097/rhu.0000000000000736.

Arthritis & RheumatologyJournal

The Evolving Art and Science of American College of Rheumatology Guidelines

Yazdany, Jinoos, Liron Caplan, John Fitzgerald, and Gabriela Schmajuk. 2018. “The Evolving Art and Science of American College of Rheumatology Guidelines”. Arthritis & Rheumatology. Wiley. doi:10.1002/art.40725.

Journal of Diabetes and its ComplicationsJournal

Coronary Artery Disease Severity Modifies Associations Between Glycemic Control and Both Mortality and Myocardial Infarction

Raghavan, Sridharan, Wenhui G. Liu, P. Michael Ho, Mary E. Plomondon, Anna E. Barón, Liron Caplan, Karen E. Joynt Maddox, et al.. 2018. “Coronary Artery Disease Severity Modifies Associations Between Glycemic Control and Both Mortality and Myocardial Infarction”. Journal of Diabetes and Its Complications. Elsevier BV. doi:10.1016/j.jdiacomp.2018.01.010.

Arthritis Care & ResearchJournal